Abstract
Obesity is a leading risk factor for cancer, but whether obesity is linked to specific genomic subtypes of cancer is unknown. Here, we examined the relationship between obesity and tumor genotype in two large clinicogenomic corpora. Obesity was associated with specific driver mutations in lung adenocarcinoma, endometrial carcinoma, and cancers of unknown primary, independent of clinical covariates and genetic ancestry. Obesity is therefore a putative driver of etiologic heterogeneity across cancers.
Competing Interest Statement
ER is a paid consultant of Xontogency LLC.
Funding Statement
This work was supported by P50 CA247749-01, P30 CA008748, the Molecular Diagnostics Service in the Department of Pathology, and the Marie-Josee and Henry R. Kravis Center for Molecular Oncology. J.J. was supported by K12 CA184746. E.R. was supported by NIH R37 CA276200 and DOD grant HT9425-23-1-0995.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All patients provided written informed consent and were prospectively sequenced as part of their active care at Memorial Sloan Kettering Cancer Center (MSKCC) as part of an Institutional-Review-Board-approved research protocol (NCT01775072).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Corrected name of co-author Alexander Gusev.
Data Availability
All clinical and genomic sequencing data described in this manuscript has been deposited in the cBioPortal for Cancer Genomics and are available for online browsing and download there. While raw sequencing data is restricted to protect patient privacy in accordance with federal and state law, de-identified data are available. De-identified data can be requested for research use from the corresponding authors. Data will be shared for a span of 2 years within 2 weeks of execution of a data transfer agreement with MSKCC, which retains all title and rights to the data and results from their use.
